Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors

E. P. Acosta, T. N. Kakuda, R. C. Brundage, P. L. Anderson, C. V. Fletcher

Research output: Contribution to journalArticlepeer-review

108 Scopus citations

Abstract

Many factors are involved in the success or failure of antiretroviral therapy. Recent data suggest that there are significant differences in drug absorption and disposition for the protease inhibitor class of antiretroviral drugs, and relationships between plasma concentrations and their antiviral effect have been described. Consequently, the issue of whether therapeutic drug monitoring should be employed for patients receiving treatment with these drugs has arisen. Several criteria must be met before a drug is considered a candidate for therapeutic drug monitoring. These criteria include pharmacological, clinical, and analytic components. Although not all the necessary criteria have yet been met, some of these components have been defined, and additional data are being generated. However, prospectively designed clinical trials must be completed to determine if monitoring protease inhibitor plasma concentrations provides additional clinical benefit to the patient.

Original languageEnglish (US)
Pages (from-to)S151-S159
JournalClinical Infectious Diseases
Volume30
Issue numberSUPPL. 2
DOIs
StatePublished - 2000

Bibliographical note

Funding Information:
Grant support: This work was supported in part by the National Institute of Allergy and Infectious Diseases (RO1 AI33835, UO1 AI38858, and UO1 AI41089).

Fingerprint Dive into the research topics of 'Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors'. Together they form a unique fingerprint.

Cite this